Gilead Sciences (GILD) closed at $168.08 on November 13, 2026, up 0.1% from the previous close, on volume of 3,229,955 shares (30-day average 6,328,455).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Ratio Put Spread 1 by 3 | 20-Nov-26140[3x] : 148 P | 17,328 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Cardinal Health (CAH)
TipRanks (Thu, 12-Nov 9:02 AM ET)
Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards
Business Wire (Thu, 12-Nov 8:30 AM ET)
Scotiabank Keeps Their Buy Rating on Gilead Sciences (GILD)
TipRanks (Tue, 10-Nov 8:26 AM ET)
TipRanks (Mon, 9-Nov 9:00 PM ET)
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
Business Wire (Fri, 6-Nov 12:16 PM ET)
Business Wire (Thu, 5-Nov 10:00 AM ET)
Gilead Lines Up 23 ASH 2026 Presentations, With anito-cel’s December 23 PDUFA Date in Focus
Market Chameleon (Wed, 4-Nov 4:35 AM ET)
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Business Wire (Wed, 4-Nov 9:15 AM ET)
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Business Wire (Mon, 2-Nov 8:30 AM ET)
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Gilead Sciences trades on the NASDAQ stock market under the symbol GILD.
As of November 13, 2026, GILD stock price climbed to $168.08 with 3,229,955 million shares trading.
GILD has a beta of 0.09, meaning it tends to be less sensitive to market movements. GILD has a correlation of 0.00 to the broad based SPY ETF.
GILD has a market cap of $208.55 billion. This is considered a Mega Cap stock.
Last quarter Gilead Sciences reported $8 billion in Revenue and $2.55 earnings per share. This beat revenue expectation by $495 million and exceeded earnings estimates by $.37.
In the last 3 years, GILD traded as high as $176.58 and as low as $62.07.
The top ETF exchange traded funds that GILD belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.
GILD has outperformed the market in the last year with a return of +36.8%, while the SPY ETF gained +13.4%. In the last 3 month period, GILD beat the market returning +22.3%, while SPY returned -2.8%. However, in the most recent 2 weeks GILD has underperformed the stock market by returning -1.5%, while SPY returned -0.2%.
GILD support price is $164.50 and resistance is $171.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GILD shares will trade within this expected range on the day.
